Michel Dahan Akebia Therapeutics, Inc. (AKBA) insider trading activity

Michel Dahan is SVP, Chief Operating Officer of Akebia Therapeutics, Inc.. Currently has a direct ownership of 672,092 shares of AKBA, which is worth approximately $1.12 Million. The most recent transaction as insider was on May 13, 2024, when has been sold 34,840 shares (Common Stock) at a price of $1.26 per share, resulting in proceeds of $43,898. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 672K

0% 3M change

17.08% 12M change

Total Value Held $1.12 Million

Michel Dahan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 13 2024	SELL Open market or private sale	$43,898 $1.26 p/Share	34,840 Reduced 4.93%	672,092 Common Stock
Feb 29 2024	SELL Open market or private sale	$13,684 $1.58 p/Share	8,661 Reduced 1.21%	706,932 Common Stock
Feb 27 2024	SELL Open market or private sale	$16,330 $1.52 p/Share	10,744 Reduced 1.48%	715,593 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	149,300 Added 17.05%	726,337 Common Stock
May 25 2023	SELL Open market or private sale	$116,483 $1.22 p/Share	95,478 Reduced 14.26%	574,037 Common Stock
May 24 2023	BUY Grant, award, or other acquisition	-	200,000 Added 23.0%	669,515 Common Stock
May 12 2023	BUY Grant, award, or other acquisition	-	200,000 Added 29.87%	469,515 Common Stock
Mar 01 2023	SELL Open market or private sale	$17,962 $0.88 p/Share	20,412 Reduced 7.04%	269,515 Common Stock
Feb 27 2023	SELL Open market or private sale	$8,172 $0.81 p/Share	10,090 Reduced 3.36%	289,927 Common Stock
Mar 01 2022	SELL Open market or private sale	$32,502 $2.17 p/Share	14,978 Reduced 4.8%	297,017 Common Stock
Feb 28 2022	SELL Open market or private sale	$14,093 $2.15 p/Share	6,555 Reduced 2.47%	258,995 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	50,000 Added 13.93%	308,995 Common Stock
Apr 01 2021	SELL Open market or private sale	$4,117 $3.4 p/Share	1,211 Reduced 0.45%	265,550 Common Stock
Mar 16 2021	BUY Grant, award, or other acquisition	-	11,648 Added 4.18%	266,761 Common Stock
Mar 01 2021	SELL Open market or private sale	$49,460 $3.4 p/Share	14,547 Reduced 5.39%	255,113 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	62,000 Added 18.69%	269,660 Common Stock

Michel Dahan

SVP, Chief Operating Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKBA shares.

Notify only if

Value

Insider Trading

Get notified when an Akebia Therapeutics, Inc. insider buys or sells AKBA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akebia Therapeutics, Inc.

Track Activities on AKBA

Account